Based on this cancer checklist context and NCCN guidelines: CANCER CHECKLIST CONTEXT: Cancer Type: Pancreatic...

Understanding BRCA and PALB2 Testing for Pancreatic Cancer

I can see you're asking about a specific webinar titled "Have I been tested for BRCA and PALB2?" — this is an important question that relates directly to your pancreatic cancer care. Let me help you understand what this testing means and why it matters.

What BRCA and PALB2 Testing Means

BRCA1 and BRCA2 are genes that normally help repair damaged DNA in your cells. When these genes have mutations (changes), your cells can't repair DNA damage properly, which increases cancer risk. PALB2 is another DNA repair gene that works similarly.

According to the NCCN Guidelines for Pancreatic Cancer, genetic testing for inherited mutations is now recommended for ANY patient with confirmed pancreatic cancer, regardless of family history. This is a significant shift — it's now standard care, not just for high-risk patients.

Why This Matters for Pancreatic Cancer Patients

• About 5-8% of pancreatic cancer patients carry BRCA1, BRCA2, or PALB2 mutations
• For patients of Ashkenazi Jewish heritage, this rate can be as high as 10-15%
• These mutations predict how well certain treatments will work for you
• Having one of these mutations opens up specific treatment options that may not be available otherwise

---

The Two Types of Testing You Should Know About

1. Germline Testing (Hereditary/Inherited Testing)

This tests your normal cells (usually via blood draw or saliva) to see if you inherited a mutation from a parent.

Why it matters:

• Tells you if the mutation runs in your family
• Helps your relatives understand their cancer risk
• According to the NCCN Guidelines, if you test positive, genetic counseling is recommended for you AND your family members
• May make you eligible for specific therapies like PARP inhibitors

2. Somatic/Tumor Testing (Tumor Molecular Profiling)

This tests the cancer cells themselves to see if mutations are present in your tumor.

Why it matters:

• Shows what's happening in YOUR specific cancer
• Helps your doctor choose targeted treatments
• The NCCN Guidelines recommend tumor molecular profiling for patients with locally advanced or metastatic disease who are candidates for treatment

---

What Answers to Look For

When you ask your doctor "Have I been tested for BRCA and PALB2?" here's what you should expect to hear:

✅ GOOD ANSWERS:

• "Yes, we did germline testing, and here are your results..."
• "Your tumor was tested for BRCA mutations, and here's what we found..."
• "You don't have a BRCA or PALB2 mutation, but we tested for it"
• "We found a BRCA2 mutation — this means you're eligible for PARP inhibitor therapy"
• "Here's a written report of your genetic testing results"

⚠️ RED FLAGS (Things to follow up on):

• "We haven't done genetic testing yet"
• "We only did tumor testing, not germline testing"
• "I'm not sure if you were tested"
• "We don't usually do that testing"
• No written report provided

---

Treatment Implications: Why Testing Matters

According to the NCCN Guidelines and recent clinical evidence, if you have a BRCA1, BRCA2, or PALB2 mutation:

Available Treatment Options:

• PARP Inhibitors (like olaparib/Lynparza) — FDA-approved for BRCA-mutated pancreatic cancer
• Platinum-based chemotherapy — often more effective in BRCA-mutated cancers
• Emerging immunotherapy combinations — being studied in clinical trials

Key Point from the Guidelines:

The NCCN Guidelines specifically note that genetic testing should identify mutations in: ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53.

---

Questions to Ask Your Oncology Team

If you haven't been tested yet, or want to understand your results better, ask:

1. "Have I had germline genetic testing (testing of my normal cells) for BRCA1, BRCA2, and PALB2?"

   • If no: "Can we order this test?"
   • If yes: "Can I see the written results?"

2. "Has my tumor been tested for BRCA mutations and other actionable mutations?"

   • Ask specifically about: BRCA1/2, PALB2, KRAS, and other mutations

3. "If I have a BRCA or PALB2 mutation, what treatment options does this open up for me?"

4. "Should my family members be tested?"

   • This is important because these are inherited mutations

5. **"Can you provide me with a written copy of my genetic testing report to keep with my [ID removed]

   • According to Dr. [removed] Strickler (in the Cancer Patient Lab webinar on pancreatic cancer), this report often lives outside your main medical chart and is crucial to have when getting second opinions

---

Important Context: The Testing Landscape is Evolving

According to the NCCN Guidelines, the recommendation for genetic testing in pancreatic cancer is relatively new. As recently as 2013, there were no targeted therapies available for pancreatic cancer mutations. Now:

• PARP inhibitors are FDA-approved for BRCA-mutated pancreatic cancer
• KRAS inhibitors are emerging as new options
• Immunotherapy combinations are being studied
• Liquid biopsies (blood tests) are being developed for earlier detection

This means your doctor should be current on these recommendations.

---

What to Do With Your Results

If you have a BRCA or PALB2 mutation:

• Discuss PARP inhibitor eligibility with your oncologist
• Consider genetic counseling
• Inform family members so they can get tested
• Ask about clinical trials for BRCA-mutated pancreatic cancer

If you don't have these mutations:

• Ask about other actionable mutations (KRAS, ATM, etc.)
• Discuss what other treatment options are available
• Still important to have molecular profiling done

---

Key Takeaway

According to the NCCN Guidelines for Pancreatic Cancer, genetic testing for BRCA1, BRCA2, and PALB2 is now standard of care — not optional. This testing can directly impact your treatment options and outcomes. Make sure you've had it done, understand your results, and have a written copy for your records.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about genetic testing and treatment options.